TORNTPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.0
| Stock Code | TORNTPHARM | Market Cap | 1,35,316 Cr. | Current Price | 3,997 ₹ | High / Low | 4,125 ₹ |
| Stock P/E | 63.4 | Book Value | 250 ₹ | Dividend Yield | 0.80 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 3,871 ₹ | DMA 200 | 3,605 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.12 % | PAT Qtr | 606 Cr. | PAT Prev Qtr | 551 Cr. |
| RSI | 55.8 | MACD | 34.1 | Volume | 1,29,205 | Avg Vol 1Wk | 3,09,844 |
| Low price | 2,886 ₹ | High price | 4,125 ₹ | PEG Ratio | 2.61 | Debt to equity | 0.25 |
| 52w Index | 89.7 % | Qtr Profit Var | 31.8 % | EPS | 62.3 ₹ | Industry PE | 29.0 |
📊 Chart Patterns: TORNTPHARM is trading at 3,997 ₹, close to its 52-week high (4,125 ₹). The price is above both 50 DMA (3,871 ₹) and 200 DMA (3,605 ₹), confirming strong bullish momentum and trend continuation.
📈 Moving Averages: Current price is comfortably above both short-term and long-term averages. The 50 DMA is above the 200 DMA, signaling a bullish crossover and sustained uptrend.
📉 RSI: At 55.8, RSI indicates moderate strength, leaning bullish but not yet overbought.
📈 MACD: Positive at 34.1, showing bullish divergence and strong buying signals.
📊 Bollinger Bands: Price is near the upper band, suggesting strong buying interest but also caution for possible short-term pullback.
📊 Volume Trends: Current volume (1.29 lakh) is lower than average weekly volume (3.09 lakh), indicating reduced participation despite price strength.
📌 Momentum Signals: Short-term momentum is bullish. Support lies around 3,870–3,900 ₹, while resistance is near 4,100–4,125 ₹.
🎯 Entry Zone: 3,880–3,920 ₹ (near 50 DMA support).
🎯 Exit Zone: 4,100–4,125 ₹ (near 52-week high resistance).
🔎 Trend Status: The stock is trending upward with strong bullish signals.
Positive
- EPS of 62.3 ₹ indicates strong profitability.
- ROCE (27.8%) and ROE (26.2%) reflect excellent capital efficiency.
- Quarterly PAT improved from 551 Cr. to 606 Cr. (31.8% growth).
- FII holdings increased by 0.21%, showing foreign investor confidence.
Limitation
- High P/E ratio (63.4) compared to industry PE (29.0) suggests overvaluation risk.
- PEG ratio of 2.61 signals expensive valuation relative to growth.
- Dividend yield of 0.80% is modest.
- Volume participation is lower than average, indicating cautious sentiment.
Company Negative News
- DII holdings decreased by -0.12%, showing reduced domestic institutional support.
- Stock price is near resistance, raising risk of short-term pullback.
Company Positive News
- Quarterly PAT growth signals improving operational efficiency.
- FII holdings increased, reflecting foreign investor interest.
Industry
- Industry PE at 29.0 suggests sector trades at lower valuations compared to TORNTPHARM’s high P/E.
- Pharmaceutical sector remains resilient with long-term demand outlook.
Conclusion
🚀 TORNTPHARM is trending upward with strong bullish technical indicators, supported by moving averages and MACD. Short-term traders may enter around 3,880–3,920 ₹ with targets near 4,100–4,125 ₹. Long-term investors should be cautious of high valuations but can hold for continued sector growth and profitability.